Cervical cancer in the Bamenda Regional Hospital, North West Region of Cameroon: a retrospective study

Ngwayu Claude Nkfusai1,2, Samuel Nambile Cumber3,4,5, Takang Williams6, Judith K Anchang-Kimbi7, Brenda Mbouamba Yankam1,8, Cho Sabastine Anye1, Joyce Mahlako Tsoka-Gwegweni3,9, Enow-Orock George Enow10, Damian Nota Anong1,11

1Department of Microbiology and Parasitology, Faculty of Science, University of Buea, Buea, Cameroon, 2Cameroon Baptist Convention Health Services (CBCHS), Yaoundé, Cameroon, 3Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa, 4Section for Epidemiology and Social Medicine, Department of Public Health, Institute of Medicine (EPSO), The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, 5School of Health Systems and Public Health Faculty of Health Sciences, University of Pretoria Private Bag X323, Gezina, Pretoria, 0001, Pretoria, South Africa, 6Faculty of Health Sciences, University of Bamenda, Bamenda, Cameroon, 7Department of Zoology and Animal Physiology, Faculty of Science, University of Buea, Buea, Cameroon, 8Department of Statistics, Faculty of Physical Science, University of Nigeria, Nsukka, Nigeria, 9School of Nursing & Public Health, College of Health Sciences, University of KwaZulu-Natal Durban, South Africa, 10Faculty of Health Sciences, University of Buea, Buea, Cameroon, 11Department of Biological Sciences, Faculty of Science, University of Bamenda, Bamenda, Cameroon

Key words: Cervical cancer, retrospective study, Regional Hospital Bamenda

Received: 21/01/2019 - Accepted: 07/02/2019 - Published: 26/02/2019

Abstract

Introduction: Cervical cancer is ranked the 7th most common cancer in the world. Cancer of the cervix is the second most commonly diagnosed cancer after breast cancer and the third leading cause of cancer deaths among females in less developed countries. Incidence rates are highest in countries with low income. Nearly 90% of cervical cancer deaths occur in developing parts of the world. The study researchers therefore, carried out a retrospective study to determine the proportion of cervical cancer among other types of cancer in the cancer registry of the Bamenda Regional Hospital. Methods: The objective of this study was to determine the proportion of cervical cancer among other types of cancers in the cancer registry of the Bamenda Regional Hospital, North West Region of Cameroon from past records. We reviewed all records from the registry of patients who attended the Bamenda Regional Hospital to screen and/or be operated upon for cervical cancer and other types of cancer. Socio-demographic and clinical characteristics of cases were captured using a data collection sheet: age, type of cancer, stage of cancer, type of surgery carried out and date of surgery. Data were entered and analysed in Statistical Package for Social Sciences (SPSS) version 25 software. Results: 59 cancer cases were received in the center between 2012 and 2017. Of these, 31 (52%) had cervical cancer. Most patients who screened positive for cancer of the cervix were of the 50-54 age groups. Most of these patients (47.5%), were received at late stages (stages 3 and 4). Conclusion: Over half (52%) of the patients receiving cancer care in this center have cervical cancer and generally turn up late for management.

Pan African Medical Journal. 2019;32:90. doi:10.11604/pamj.2019.32.90.18217

This article is available online at: http://www.panafrican-med-journal.com/content/article/32/90/full/

© Ngwayu Claude Nkfusai et al. The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

Cervical cancer is ranked the 7th most common cancer in the world. Cervical cancer is the second most commonly diagnosed cancer after breast cancer and the third leading cause of cancer deaths among females in less developed countries. Incidence rates are highest in countries with low income. Nearly 90% of cervical cancer deaths occurred in developing parts of the world. The cervix is divided into two halves; the endo-cervix, which is made up of columnar epithelium and the exo-cervix made up of squamous epithelium. The two halves merge at the squamo-columnar junction (SCJ), an important zone for malignant transformation. The SCJ varies in position throughout the reproductive life of a woman with an outward trend into the vagina. Cervical dysplasia, precancerous lesions in the cervical transformation zone can lead to cervical cancer [1]. Cervical cancer is preventable and curable if early diagnosed. The causative agent of the disease is the Human Papilloma Virus (HPV) which is transmitted through sexual intercourse causing cervical cancer through a slow growth over a period of 10-20 years [1]. There are over 150 different types of HPV; more than 40 can infect the cervix and are sexually transmitted, causing 99.4% of cervical cancer cases and 100% of genital warts cases. Out of the 150 types, about a dozen are carcinogenic. HPV-16 accounts for 50% to 55% of all cases of invasive cervical cancer worldwide while HPV-18 accounts for an additional 10% to 15%. Highly Active Antiretroviral Therapy (HAART) and evolution of cervical disease causes a high prevalence of cervical cancer in Cameroon [2]. Strains 16 and 18 are known to be responsible for up to 70% of cervical cancer worldwide [3]. It has been proven that, at least 50% of women who are sexually active have suffered an infection with at least one strain of HPV [4]. The global incidence of cervical cancer is greater than 530,000 annually, with death approaching 275,000 per year [5]. The prevalence of cervical cancer worldwide is estimated by [6] to be 12%. One of the most important reasons for the incidence of cervical cancer in developing countries is the lack of early detection of pre-cancerous lesions and treatment of the lesions before they progress [7].

Among the newly diagnosed cases, 86% are reported in poor countries. Also, 88% of deaths resulting from cervical cancer are in the low-income countries [8]. In Africa, the incidence is 80,000 per annum, with an annual mortality of 75%; most of the cases are seen in sub-Saharan Africa [8]. It was shown that cervical cancer prevalence was up to 13.8%; this is based on a study carried out in the capital city Yaounde [9]. More than 6 million Cameroonian females who are aged 15 and above are at risk of developing cervical cancer, and there are 1993 new cases of cervical cancer yearly, of which 1120 die of the disease annually [3]. In poor countries, awareness as well as uptake of cervical cancer screening services has remained poor over the years. Several studies done in communities and among women in sub-Saharan Africa revealed that knowledge were generally poor [10]. Risk factors of cervical cancers have also been highly demonstrated among Cameroonian women, especially the rural women [11]. Mogtomo and colleagues [12] have demonstrated a high incidence of sexually transmissible infections, multiple sexual partners, low use of condoms and other risk factors of cervical cancer among students in the University of Douala [13]. This therefore, calls for relevant measures to reduce this trend of progression. With current and appropriate measures put in place to prevent cervical cancer, success of screening will largely depend on the awareness and beliefs among women. The knowledge level of the general population is very important in determining the right strategy in planning an effective intervention against cervical cancer. WHO [2] reported that cervical cancer screening coupled with immediate management leads to early detection of precancerous and cancerous cervical lesions, thus preventing serious morbidity and mortality due to the cervical cancer disease'. In a study carried out by [14-17], they demonstrated that the level of awareness of HPV infection and prevention of cervical cancer is moderately low in Cameroon. Gardasil for HPV 6 and 11, and Cervarix for HPV 16 and 18 are available in the market for cervical cancer [17].

Methods

Study design, setting and population: The study was conducted in the Bamenda Regional Hospital, North West Region of the Republic of Cameroon. Bamenda is a city in North Western Cameroon and capital of the North West Region. The city has a population of about 500,000 people. Bamenda is situated at 5.95° North latitude, 10.16° East longitude and 1472 meters elevation above the sea level. In the cancer department where registration, screening and surgery for cancer are done is one of the 18 units of the Bamenda Regional Hospital. These units include, the Directorate and its Secretariat, Laboratory department, Day Care (which capture all HIV/AIDS, testing and treatment of cases), Diabetic/
Hypertensive unit, Ear, Nose and Throat Department, Dental Department, Out Patient Department, Social Service, Obstetric/Gynaecologic, Theatre, General/Infant Consultation Department, Equipment Department, Sanitary Department, Mortuary, Palliative Care and the Obstetric/Gynaecologic Department.

Selection criteria

Inclusion criterion: All women managed for cancer from 2012 to 2017 in the centre were included in the final analysis.

Exclusion criterion: All negative results.

Sample size and sampling: All patients' records were checked.

Data collection: All patient's files were thoroughly checked and data on age, sex, type of cancer, type of surgery carried out and the year of surgery were captured into an excel template.

Data analyses: Data was entered into Excel, verified for completeness. Incomplete entries were deleted and cleaned before analyses. Descriptive data analysis in the form of tables, pie charts, and bar or column charts were used.

Ethical considerations: Ethical clearance was obtained from the Institutional Ethical Review Board of the Faculty of Health Sciences, University of Buea. Authorization to use the cancer registry was gotten from the Directorate of the Regional Hospital Bamenda who are the custodians of the cancer registry. Confidentiality and integrity of the data were maintained by restricting access of the information and primary data to the Principal Investigator.

Results

Availability of cancer data: 59 cancer cases were received during the study period (2012 to 2017). Figure 1 shows the proportions of the different cancer types in patients who consulted at the cancer centre of the Bamenda Regional Hospital.

Cancer types and types of surgery: 6 different types of cancers (cervical cancer, breast cancer, endometrial cancer, adenocarcinoma of the colon, ovarian cell tumor and vulva carcinoma) were diagnosed within this period. Abdominal hysterectomy was the most common type of surgery done for all the cancers. The surgeries were carried out within the study period (Table 1, Figure 1).

Cervical cancer types and stages: Cancer of cervix, cervical lesion, precancerous cervix, squamous cell carcinoma and cervical dysplasia were the types of cervical cancer, we found cancer of the cervix occurring the highest with 16 out of the 31 cases. Stage III was the most frequent stage of cervical cancer diagnosed (Table 2). Cervical cancer ranked first in all cases reported during this period with 31(52%) cases (Figure 2).

Age distribution of cervical cancer: The youngest patient was 31 years old while the oldest patient was 69 years. Most cases were between the ages of 50-54 years. The minimum age group of cervical cancer was 30-34 years while the maximum was 65-69 years with the highest number of cervical cancer cases found in the 50-54 years age group (Figure 2).

Discussion

Cancer of the cervix was the predominant type of cancer (52.2%) in the Bamenda Regional Hospital. This was far higher than 13.8% reported by [9] 2012 in Yaounde-Cameroon, and 29.9% reported by [17] 2013 in Yaounde-Cameroon. Their study results were derived from pathology results while ours was derived from surgery. It was also, different from a study conducted in 6 regions in Cameroon to determine the prevalence of cervical premalignant lesions from where; the national prevalence was 3.9% [15]. This difference could be due to the fact that, Tebeu and colleagues [15] had a larger sample size than our study and their study was representative. One of the most important reasons for the incidence of cervical cancer in developing countries is the lack of early detection of pre-cancerous lesions and treatment of the lesions before they progress [7].

Atashili and colleagues [16] also, reported a prevalence of 11.5% of SIL due to cervical disease in women receiving HAART in Cameroon. This was far lower than the 52% obtained in our study, it could however be different because our study was not limited to HIV/AIDS patients receiving HAART. Torre and colleagues [7] reported that cervical cancer is the second most commonly diagnosed cancer after breast cancer and the third leading cause of cancer deaths among females in less developed countries. From our study, cervical cancer ranked first, followed by breast cancer. This difference could be due
to the fact that our study concentrated on just one region while that of Torre and colleagues [7] was carried out in several other regions. The highest age group with cervical cancer was 50-54; this is similar to the age at high risk of many types of cancer. Completeness of registration of cancer cases in this population was estimated at about 50%.

**Some limitations in our study includes:** Limited demographic information available for the women who were screened positive for cervical cancer; the fact that the researchers did not screen the women for cervical cancer but rather collected data from hospital records to determine the prevalence of cervical cancer is the reason for limited demographic information. Despite this shortcoming, this study provides relevant information in the context of very limited epidemiological data on the prevalence of cervical cancer among other types of cancers in the cancer registry of the Bamenda Regional Hospital, North West Region of Cameroon.

**Conclusion**

The proportion of cervical cancer (52%), among other types of cancers found in the cancer registry of the Bamenda Regional Hospital is high. The most affected group with cervical cancer was 50-54 year old group; which is similar to the age with a high risk to develop most cancers.

**What is known about this topic**

- Cameroon in the year 2000, it revealed a prevalence of 7.9%, and the age of first intercourse as the major risk factor (the prevalence of cervical cancer in Cameroon in 2000 stood at 7.9%, which main risk factor being age at first sexual intercourse);
- Cervical cancer is the second most commonly diagnosed cancer after breast cancer 80 000 per annum, with an annual mortality of 75%; with most of the cases are seen in sub-Saharan Africa;
- More than 6 million Cameroonian females who are aged 15 and above are at risk of developing cervical cancer, and there are 1993 new cases of cervical cancer yearly, of which 1120 die of the disease annually.

**What this study adds**

- Over half (52%) of cancers managed in the Bamenda Regional Hospital are cervical cancers;
- Most cancer patients seen are above 50 years of age;
- Most cancer cases are referred late in the disease course.

**Competing interests**

The authors declare no competing interests.

**Authors’ contributions**

NCN, SNC, TW, KJA, BMY, CSA, JMTG and ADN conceived and designed the study. NCN implemented the study. NCN, TW and ADN conducted data analysis. AND, KJA and SNC supervised the study. NCN, SNC, TW, KJA, BMY, CSA, JMTG and ADN interpreted study results: NCN wrote the first draft of the manuscript. SNC reviewed and corrected the draft manuscript. All authors read and approved the final manuscript.

**Acknowledgments**

We are grateful to the Directorate of the Bamenda Regional Hospital for allowing us to have access to their data.

**Tables and figures**

**Table 1:** Cancer types, type of surgery and the year of surgery
**Table 2:** Cervical cancer types and stages
**Figure 1:** Proportions of different cancer types in patients consulting at the cancer registry of Bamenda Regional Hospital
**Figure 2:** Cervical cancer distribution in patients of various ages consulting at the cancer registry of Bamenda Regional hospital

**References**

1. Daniel A, Aruna P, Ganesan S, Joseph L. Biochemical assessment of human uterine cervix by micro-Raman mapping. Photodia & Photodyn Ther. 2017; 1 (17): 65-74. PubMed | Google Scholar
2. World Health Organization. WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention: supplemental material: GRADE evidence-to-recommendation tables and evidence profiles for each recommendation. World Health Organization. 2013. Google Scholar

3. Coste J, Cochand-Priollet B, de Cremoux P, Le Galès C, Isabelle C, Vincent M, Labbé S, Vacher-Lavenu MC, Vielh P. Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening. BMJ. 2003; 326(7392): 73. PubMed | Google Scholar

4. DeGregorio GA, Bradford LS, Manga S, Tih PM, Wamai R, Ogembo R, Sando Z, Liu Y, Schweiger C, Rao SR, Kalmakis K. Prevalence, predictors, and same day treatment of positive VIA enhanced by digital cervicography and histopathology results in a cervical cancer prevention program in Cameroon. PloS one. 2016; 11(6): e0157319. PubMed | Google Scholar

5. Kafuruki L, Rambau PF, Massinde A, Masalu N. Prevalence and predictors of cervical intraepithelial neoplasia among HIV infected women at Bugando Medical Centre, Mwanza-Tanzania. Infect Agents and Cancer. 2013; 8(1):45. PubMed | Google Scholar

6. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FA, Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA: A Cancer J Clin. 2012; 62(3):147-72. PubMed | Google Scholar

7. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA A Cancer J Clin. 2015; 65(2): 87-108. PubMed | Google Scholar

8. Lim JN, Ojo AA. Barriers to utilisation of cervical cancer screening in Sub Sahara Africa: a systematic review. Euro J Cancer Care. 2017; 26(1): e12444. PubMed | Google Scholar

9. Enow Orock GE, Ndom P, Doh AS. Current cancer incidence and trends in Yaounde, Cameroon. Oncol Gastroentero Hepatol Reports. 2012; 1(1):58-63. Google Scholar

10. Nakibuule C. Knowledge, attitudes and practices regarding cervical cancer among women and men in Kampala City, Uganda. 2014. Google Scholar

11. Tufon EN, Novert Y, Simeone E, Noel N. Prevalence, associated risk factors and methods of diagnosing cervical cancer in two hospitals in Yaounde, Cameroon. Intern J Advan Research in Pharma & Bio Sc. 2013; 2(2):55-60. Google Scholar

12. Mogtomo ML, Malieugoue LC, Djiepgang C, Wankam M, Moune A, Ngane AN. Incidence of cervical disease associated to HPV in human immunodeficiency infected women under highly active antiretroviral therapy. Infect Agents and Cancer. 2009; 4(1): 9. PubMed | Google Scholar

13. Koanga MM, Ngonou NA, Wandjis A, Dongang NR, Donfack TH, Nganwa G, Wankam M, Amvam ZP. Sexual behaviour: human papilloma virus and cervical cancer risk among university students in cameroon. Afric J Haemato Oncol. 2010; 1(4). Google Scholar

14. Wamai RG, Ayissi CA, Oduwo GO, Perlman S, Welty E, Welty T, Manga S, Onyango MA, Ogembo JG. Awareness, knowledge and beliefs about HPV, cervical cancer and HPV vaccines among nurses in Cameroon: An exploratory study. Inter J Nursing Studies. (2013); 50(10): 1399-406. PubMed | Google Scholar

15. Tebeu PM, Sandjong I, Nkele N, Fokoua S, Achu P, Kouam L, DOH AS. Lesions pre cancéreuses du col utérin en zone rurale: Etude transversale. Medecine d?Afrique noire. 2005; 2005(52):1. Google Scholar

16. Atashili J, Adimora AA, Ndumbe PM, Ikomey GM, Rinas AC, Myers E, Eron J, Smith JS, Miller WC. High prevalence of cervical squamous intraepithelial lesions in women on antiretroviral therapy in Cameroon: Is targeted screening feasible? Cancer Epid. 2012; 36(3): 263-9. PubMed | Google Scholar
17. Bhatla N, Berek JS, Cuello Fredes M, Denny LA, Grenman S, Karunaratne K et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2019. PubMed | Google Scholar
Table 1: cancer types, type of surgery and the year of surgery

| S/N | Age | Type of cancer | Stage | Type of Surgery | Date of Surgery |
|-----|-----|----------------|-------|-----------------|-----------------|
| 1   | 35  | Severe cervical dysplasia | CIN III/Intraepithelial neoplasia | Total abdominal hysterectomy | 26/11/16 |
| 2   | 45  | Precancerous lesions of the cervix plus urinary incontinence | CIN III | Total hysterectomy plus BSO suspension | 18/11/16 |
| 3   | 42  | Cervical neoplasia | Stage 1B | Total abdominal hysterectomy | 06/12/14 |
| 4   | 38  | Severe cervical dysplasia | CIN III | Total abdominal hysterectomy | 13/12/14 |
| 5   | 42  | Endometrial carcinoma plus uterine fibroid | Stage 1 | Total abdominal hysterectomy | 06/01/15 |
| 6   | 69  | Cervical cancer | Stage 1B | Involved cervical cancer stage 1B | 06/02/15 |
| 7   | 41  | Non keratinized moderately differentiated squamous carcinoma | Stage 1B | Wertheim's hysterectomy | 20/12/16 |
| 8   | 51  | Cervical cancer | Stage 2B | Biopsy | 20/12/16 |
| 9   | 53  | Precancerous lesions of the cervix | CIN III | Laporatomy | 27/03/15 |
| 10  | 20  | Ovarian tumor | Stage 3 | Exploratory laparatomy | 17/01/12 |
| 11  | 41  | Cervical cancer | CIN III | Laporatomy | 26/12/12 |
| 12  | 41  | Breast cancer | T2N0Mo | Radical left mastectomy | 21/04/16 |
| 13  | 41  | Breast cancer | T2N1NO | Radical left mastectomy | 24/01/13 |
| 14  | 69  | Cervical cancer | Carcinoma in situ | Total abdominal hysterectomy | 24/01/12 |
| 15  | 50  | Breast cancer | T2N0Mo | Mastectomy | 13/03/13 |
| 16  | 48  | Cervical cancer | Stage 1A | Total hysterectomy | 02/06/16 |
| 17  | 37  | Breast cancer | Intraductal carcinoma of left breast | Left total mastectomy and axillary clearance | 04/06/16 |
| 18  | 37  | Bilateral breast cancer | T3N2M2 | Bilateral mastectomy and lymph nodes | 10/06/16 |
| 19  | 55  | Cervical cancer | Stage 1A | Total abdominal hysterectomy | 15/07/13 |
| 20  | 60  | Breast neoplasia | T2N0Mo | Left total mastectomy | 24/02/12 |
| 21  | 35  | Breast cancer | T2N0Mo | Mastectomy plus axillary clearance | 14/11/13 |
| 22  | 42  | Lobular carcinoma | T4N1M0 | Radical mastectomy | 31/10/16 |
| 23  | 51  | Pre cervical cancer | CIN III | Total hysterectomy | 06/11/16 |
| 24  | 44  | Vagina, vulva plus genital warts | Stage 2B | Vulvectomy | 06/11/16 |
| 25  | 54  | Cervical cancer | Stage 2B | Total abdominal hysterectomy | 06/11/16 |
| 26  | 34  | Cervical cancer | Stage 2A | Wertheim's hysterectomy | 06/11/16 |
| 27  | 50  | Cervical cancer | Stage 1B | Wertheim's hysterectomy | 06/11/16 |
| 28  | 54  | Cervical cancer squamous cell carcinoma | Stage 2B | Wertheim's hysterectomy | 06/11/16 |
| 29  | 34  | Cervical cancer | 4 | Radio/chemo | 06/11/16 |
| 30  | 58  | Adenocarcinoma colon | 4 | Radio/chemo | 06/11/16 |
| 31  | 50  | Cervical cancer | 4 | Radio/chemo | 06/11/16 |
| 32  | 33  | Cervical Cancer | 4 | Quadrantectomy | 06/11/16 |
| 33  | 61  | Cancer of cervix | 4 | Radio/chemo | 06/11/16 |
| 34  | 52  | Cervical cancer | Stage 4 | Radio/chemo | 06/11/16 |
| 35  | 47  | Cancer of the right breast | Stage 1 | Quadrantectomy ateronecromy chemo, radiotherapy | 06/11/16 |
| 36  | 46  | GA of right breast invasive ducts carcinoma | 1B | Mastectomy plus lymphadentectomy | 06/11/16 |
| 37  | 41  | Cervical cancer | 1B | TAH | 06/11/16 |
| 38  | 62  | Cervical cancer | 1B | TAH | 06/11/16 |
| 39  | 21  | Cancer of the right breast plus pregnancy | T3N0Mo | Lost to follow-up | 06/11/16 |
| 40  | 44  | Precancerous lesions of the cervix | CIN2/CIN3 | Total hysterectomy | 06/11/16 |
| 41  | 42  | Suspected left ovarian tumor | Stage 2 | Total abdominal hysterectomy plus BSO | 20/01/17 |
| 42  | 54  | Epidermoid carcinoma | Stage 1B | Total hysterectomy, Wertheims hysterectomy | 31/01/16 |
| 43  | 28  | Left breast cancer | T2N0Mo | Total left mastectomy | 08/02/17 |
| 44  | 39  | Cervical lesion suspected malignant | Total hysterectomy | 27/01/17 |
| 45  | 46  | Cervical cancer | CIN3 | Wertheim's hysterectomy | 31/07/16 |
| 46  | 80  | Endometrial hyperplasia in menopause | Stage 1 | Total abdominal hysterectomy | 15/07/15 |
| 47  | 56  | Precancerous cervix | CIN III | Total hysterectomy | 26/06/15 |
| 48  | 68  | Moderate cervical dysplasia | CIN II | Total hysterectomy | 28/05/15 |
| 49  | 63  | Granulosa cell tumor | Stage 2 | Debulking surgery | 06/11/16 |
| 50  | 64  | Squamous cell carcinoma | Stage 1A | Total abdominal hysterectomy | 06/11/16 |
| 51  | 48  | Breast cancer | T2N0Mo | Mastectomy | 06/11/16 |
| 52  | 70  | Granulosa cell tumors | Stage 2 | Debulking surgery | 06/11/16 |
| 53  | 50  | Ovarian carcinoma | T3N1M1 | TAH | 06/11/16 |
| 54  | 42  | Adenocarcinoma | Stage 1B | TAH plus radiotherapy | 06/11/16 |
| 55  | 47  | Breast cancer | T2N | Mastectomy and radiotherapy | 06/11/16 |
| 56  | 36  | Ovarian carcinoma | T4N1M1 | Bilateral chemotherapy | 06/11/16 |
| 57  | 38  | Breast lump | T2N1M1 | Mastectomy | 06/11/16 |
| 58  | 70  | Breast cancer | T3N1M1 | Mastectomy | 06/11/16 |
| 59  | 40  | Ovarian carcinoma | T3N1M1 | Mastectomy | 06/11/16 |
| S/N | Age | Type of Cancer                                      | Stage                                      |
|-----|-----|----------------------------------------------------|--------------------------------------------|
| 1   | 31  | Severe cervical displasia                          | CIN III (Cervical intraepithelial neoplasia) |
| 2   | 44  | Precancerous lesions of the cervix plus urinary incontinence | CIN III                                    |
| 3   | 42  | Cervical neoplasia                                 | Stage 1B2                                 |
| 4   | 38  | Severe cervical dysplasia                          | CIN III                                    |
| 5   | 69  | Cervical cancer                                    | Invasive cervical cancer stage 1B          |
| 6   | 43  | Non keratinized moderately differentiated squamous carcinoma | Stage 1B                                   |
| 7   | 45  | Cancer of cervix                                   | Stage 2B                                  |
| 8   | 53  | Precancerous lesions of the cervix                 | CIN III                                    |
| 9   | 69  | Cervical cancer                                    | Carcinoma insitu                          |
| 10  | 40  | Cervical cancer                                    | Cervical dysplasia CIN3                    |
| 11  | 48  | Cervical cancer                                    | Stage 1A                                  |
| 12  | 55  | Cervical cancer                                    | Stage 1A                                  |
| 13  | 51  | Pre-cervical cancer                                | CIN III                                    |
| 14  | 34  | Cervical cancer                                    | 2A                                        |
| 15  | 50  | Cervical cancer                                    | 1B                                        |
| 16  | 54  | Cervical cancer squamous cell carcinoma            | 2B                                        |
| 17  | 34  | Cervical cancer                                    | 4                                         |
| 18  | 50  | Cervical cancer                                    | 4                                         |
| 19  | 33  | Cervical Cancer                                    | 4                                         |
| 20  | 61  | Cancer of cervix                                   | 4                                         |
| 21  | 52  | Cervical cancer                                    | Stage 4                                   |
| 22  | 43  | Cervical cancer                                    | 1B                                        |
| 23  | 62  | Cervical cancer                                    | 1B                                        |
| 24  | 39  | Cervical lesion suspected malignant                 | CNIII                                     |
| 25  | 46  | Cervical cancer                                    | CIN3                                      |
| 26  | 56  | Precancerous cervix                                | CIN III                                    |
| 27  | 68  | Moderate cervical dysplasia                         | CIN II                                    |
| 28  | 52  | Squamous cell carcinoma                            | Stage I A                                 |
| 29  | 36  | Ductal carcinoma                                   | T4N1M1                                    |
| 30  | 44  | Precancerous lesions of the cervix plus urinary incontinence | CIN III                                   |
| 31  | 52  | Squamous cell carcinoma                            | Stage I A                                 |
Figure 1: Proportions of different cancer types in patients consulting at the cancer registry of Bamenda Regional Hospital
**Figure 2**: Cervical cancer distribution in patients of various ages consulting at the cancer registry of Bamenda Regional hospital